Dr. Elena Zamagni (Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy) discusses a study investigating the role of FDG PET/CT in smoldering multiple myeloma. In the study, the presence of an FDG PET/CT focal (not osteolytic) lesion or lesions identified a sub-group of patients with smoldering multiple myeloma with high-risk of progression into symptomatic disease. The study results were presented at the 56th American Society of Hematology (ASH) Annual Meeting. ASH 2014 abstract 3371.


Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Elena Zamagni, MD1*, Cristina Nanni, MD2*, Francesca Gay, MD3*, Annalisa Pezzi, Statistician4*, Marilena Bellò, MD5*, Ilaria Rambaldi, MD2*, Paola Tacchetti, MD4*, Annamaria Brioli, MD4*, Lucia Pantani, MD4*, Valeria Magarotto, MD3*, Beatrice Anna Zannetti, MD4*, Massimo Menga, MD5*, Giulia Marzocchi, PhD4*, Carolina Terragna, PhD4*, Katia Mancuso, MD4*, Antonio Palumbo, MD3, Stefano Fanti, MD2* and Michele Cavo, MD1*

1Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
2Institute of Nuclear Medicine, Bologna University School of Medicine, Bologna, Italy
3Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
4"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
5Institute of Nuclear Medicine, Department of Imaging, University of Torino, Torino, Italy

Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder whose risk of progression to symptomatic MM (MM) is highly variable. Therefore, the identification of predictors of progression into MM is a relevant end point. Several markers (serum M protein, percentage of bone marrow plasma cells, free light chain, FLC, ratio, immunophenotyping of aberrant plasma cells and focal lesions, FLs  at MRI) have already been established to identify  sub-groups of SMM patients (pts) with a highest risk of progression into MM. Among imaging methods, FDG-PET/CT is a reliable technique for assessing early skeletal involvement and for predicting outcomes at the onset of  MM. However, no data are available regarding the impact of PET/CT FLs in SMM on time to progression (TTP) into symptomatic disease.

To address this issue, we prospectively studied pts with a suspected diagnosis of SMM with FDG-PET/CT. A cohort of 73 pts, with a median age of 61 years old (range 27-83) and a confirmed diagnosis of SMM, followed for a median of 2.2 years, is herein reported. By study design, all the pts were studied with PET/CT at baseline. Bone marrow involvement was described as negative, diffuse or focal. The number of  FLs, as well as size and associated standardized uptake values (SUV) were recorded. For each FL, the presence of eventual underlying osteolytic lesion  was investigated by the CT part of the scan; pts with osteolytic lesions were excluded from the present study, as they were considered as having symptomatic MM. Follow-up took place every 3-4 months and included clinical history, serum and urine markers and PET/CT plus axial MRI for occurrence of symptoms or an increase in M component. Progression to MM was defined by the presence of CRAB features. Skeletal progression was defined by the appearance of one or more sites of osteolytic bone destruction, pathological fractures and/or soft masses at PET/CT or MRI. The start of systemic therapy was defined as the date of event for the analysis of TTP.

Baseline patient characteristics were as follows: 83% had IgG isotype, 8% IgA and 9% BJ, with a median M component of 2.5 g/dL; 70% had ISS stage I, 23% stage II and 7% stage III. Median plasma cell involvement on bone marrow (BMPC) was 30% (range 5-100%), with 16% of the pts having more than 60% BMPC. The median serum involved/uninvolved FLC ratio was 14.39 (range 1.28-2255), with 11% of the pts presenting with a ratio ≥ 100. PET/CT was negative in 64/73 pts (88%) and positive in 9/73 (12%) of them; 5 pts had 1 FLs, 1 pt 2 FLs, 2 pts more than 3 FLs and 1 pt a diffuse bone marrow involvement. Median SUV max value was 4.45 (range 2.5-5.2). No significant differences between patients with positive or negative PET/CT were found regarding the other baseline characteristics.

At the time of the present analysis, 63% of the pts remained in the asymptomatic phase while 37% of them progressed to MM, in a median time of 4 years, including 21% with skeleton involvement, with/without the appearance of other CRAB symptoms, and 16% with exclusive serological signs of progression. Sixty six per cent of the pts with positive PET/CT progressed to MM in comparison to 33% of the pts with negative PET/CT (P = 0.034). The relative risk of progression of the pts with a positive PET/CT was 2.3 (95% CI 09.-5.9, P= 0.06). Moreover, the relative risk of skeletal progression was 4.0 (95% CI 1.3-12, P= 0.013), with a median TTP of 2.2 years for pts with positive PET/CT versus 7 years for those with negative PET/CT (figure 1). The probability of progression within  2 and 3 years for pts with positive PET/CT was 48% and 65%, respectively, in comparison to 32% and 42% for negative pts.

In conclusion, approximately 10% of the pts with SMM have a positive PET/CT, mainly with few FLs, without underlying osteolytic lesion, with a low FDG uptake. PET/CT positivity significantly increased the risk of progression of SMM into active MM. PET/CT could become a new risk factor to define high risk SMM. A larger cohort of pts will be presented at the meeting. Further studies  are warranted to find and optimal cut off point of FLs to capture the higher risk of progression at 2 year and to merge with other prognostic factors.

Download PDF


ABOUT ELENA ZAMAGNI, MD PhD

Elena Zamagni MD, PhD, is an Assistant Professor of Hematology at the University of Bologna, Italy. She received her medical degree from the University of Bologna. She has published over 90 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She is an active member of the board of the GIMEMA myeloma working party and she has cooperated in the Scientific secretary and as principal investigator in several national randomized trials in multiple myeloma. She is a member of the Italian Society of Haematology and of the International Myeloma Working Group. She is serving on the EHA’s Scientific Program Committee since 2017. Visit Dr. Elena Zamagni’s full biography.

Previous Post
Dr. Martha Lacy: Pomalidomide+ low-dose dexamethasone in relapsed/refractory myeloma (ASH 2014)
Next Post
Dr. Torben Plesner on daratumumab/lenalidomide/dexamethasone in RRMM (ASH 2014)

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.